TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02467010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
Study: NCT00447161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Clausii Multi ATB Resist
Description: Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00844688

Intervention type: DRUG
Group type: OTHER
Intervention: sorafenib
Description: Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~1. Progression of disease.~2. The patient is unlikely to benefit from further treatment as~   Judged by the Investigator.~3. Intolerable toxicity of the drugs.~4. Withdrawal of consent for any reason.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 \& 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason.
Study: NCT00848081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg taken by mouth once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: By mouth once daily for 12 weeks
Study: NCT03757689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide Excision and Sentinel Lymph Node (SLN) Biopsy
Description: Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
Study: NCT04026867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linkage Navigation
Description: The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Referral
Description: The Clinician Referral arm will serve as an active control and baseline standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Referral
Description: The Clinician Referral arm will serve as an active control and baseline standard of care.
Study: NCT03906903

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Stimulation
Description: Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Stimulation
Description: Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
Study: NCT04411875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg
Description: The subjects randomly received single oral administration of amlodipine 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine 5 mg
Description: The subjects randomly received single oral administration of levamlodipine 5 mg.
Study: NCT04170114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Respiratory Physiotherapy
Description: All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Respiratory Physiotherapy
Description: All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
Study: NCT04771507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
Study: NCT00511667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0941
Description: MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
Study: NCT02056704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiography with IVUS
Description: The use of IVUS to evaluate dialysis access failure.
Study: NCT03032731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website and pedometer intervention
Description: Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
Study: NCT02001415

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Description: Orthokeratology lenses.
Study: NCT03069170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
Study: NCT03032731

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard, publicly available NHS resources for healthy lifestyles.
Study: NCT01679977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrational-proprioceptive Resistance Exercise Training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation Training
Study: NCT04161560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: does of Cetuximab-IRDye800
Study: NCT03847454

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: REACH
Description: The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
Study: NCT01618383

Intervention type: OTHER
Group type: OTHER
Intervention: colonoscopy or rectosigmoidoscopy
Description: Usual procedure
Study: NCT03234855

Intervention type: DEVICE
Intervention: LMD
Description: Physician uses LMD to measure defect during procedure.
Study: NCT05660902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROM Exercises
Description: The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
Study: NCT02664051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalcrom
Description: Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg 4x2 daily mannitol
Study: NCT02200328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
Study: NCT02673476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176
Description: ALS-008176 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo tablets
Study: NCT00985907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil, melphalan, bortezomib
Description: Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2
Study: NCT04125056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone Capsule(Specification: 30 mg / grain）
Description: Test group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydronidone Capsule(Specification: 15 mg / grain）
Description: Control group
Study: NCT01367223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solution of amino acids supplemented with glutamine
Description: parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: amino acids not supplemented with glutamine
Description: parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
Study: NCT01480713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress® (Raltegravir, 400 mg every 12 hours)
Description: Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress® (Raltegravir, 400 every 12 hours)
Description: Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
Study: NCT02801721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho social stimulation
Description: The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
Study: NCT04096820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uromune
Description: 2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
Study: NCT03847454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care for rehabilitation treatment for musculoskeletal patients.
Study: NCT04398173

Intervention type: DIAGNOSTIC_TEST
Intervention: multiparametric MRI
Description: T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: multiparametric MRI
Description: T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
Study: NCT04318834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumour and germline molecular profiling
Description: Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
Study: NCT03898505

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AvoMax (Low Dose)
Description: AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AvoMax (High Dose)
Description: AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
Study: NCT03674515

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Smartphone application placebo
Description: Strategy based on smartphone application placebo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone equipped with application bouge = Coach group
Description: Strategy based on smartphone application bouge
Study: NCT00974805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 500 Accuhaler
Description: Seretide 500 accuhaler one inhalation BD
Study: NCT01939288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation, followed by intermittent pneumatic compression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression, followed by neuromuscular stimulation
Study: NCT01065623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY79-4620
Description: 1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
Study: NCT02062918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal belt
Study: NCT04007094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ViviGen Cellular Bone Matrix
Description: ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
Study: NCT01000441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab, etanercept, adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abatacept, rituximab or tocilizumab
Study: NCT04147221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem-relebactam
Description: After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
Study: NCT03968484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet transfusion
Description: Transfusion of platelets
Study: NCT02279719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
Study: NCT01360398

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sputum sample
Description: Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urine sample
Description: Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: End tidal breath sample
Description: Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Patient interview, diary cards review and questionnaires completion

Intervention type: OTHER
Group type: OTHER
Intervention: Tests
Description: Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
Study: NCT03155334

Intervention type: OTHER
Group type: OTHER
Intervention: PIS User Testing
Description: PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback.

Intervention type: OTHER
Group type: OTHER
Intervention: PIS User Testing
Description: PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback.
Study: NCT03461731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 800 nm laser
Description: 800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combination laser
Description: 800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 905 nm laser
Description: 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips